SG11201900125PA - Novel processes for preparation of soluble guanylate cyclase stimulators - Google Patents

Novel processes for preparation of soluble guanylate cyclase stimulators

Info

Publication number
SG11201900125PA
SG11201900125PA SG11201900125PA SG11201900125PA SG11201900125PA SG 11201900125P A SG11201900125P A SG 11201900125PA SG 11201900125P A SG11201900125P A SG 11201900125PA SG 11201900125P A SG11201900125P A SG 11201900125PA SG 11201900125P A SG11201900125P A SG 11201900125PA
Authority
SG
Singapore
Prior art keywords
international
massachusetts
compound
preparation
english
Prior art date
Application number
SG11201900125PA
Inventor
Song Xue
Vishnu Vardhan Reddy Karnati
Robert C Livingston
Timothy Claude Barden
Wayne C Schairer
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of SG11201900125PA publication Critical patent/SG11201900125PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/14—Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101111 0 11101 010 11111 01 110 1 0 011101 11011101 100 1101 011 MI MI OM Organization International Bureau (10) International Publication Number (43) International Publication Date .....se' WO 2018/009602 A3 11 January 2018 (11.01.2018) W I PO I PCT (51) International Patent Classification: dy; 18 Maybury Road, Sudbury, Massachusetts 01776 CO7D 413/14 (2006.01) A61K 31/53 (2006.01) (US). LIVINGSTON, Robert C.; 63 Stowecroft Road, Ar- C07C 209/00 (2006.01) A61P 9/00 (2006.01) lington, Massachusetts 02474 (US). BARDEN, Timothy C07D 263/34 (2006.01) Claude; 19 Intervale Road, Salem, Massachusetts 01970 (21) International Application Number: (US). SCHAIRER, Wayne C.; 135 Milk Street, Westboro, PCT/US2017/040817 Massachusetts 01581 (US). (22) International Filing Date: (74) Agent: DAVIS, Steven, G.; McCarter & English, LLP, 265 Franklin Street, Boston, Massachusetts 02110 (US). 06 July 2017 (06.07.2017) (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (30) Priority Data: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/359,430 07 July 2016 (07.07.2016) US DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (71) Applicant: IRONWOOD PHARMACEUTICALS, INC. KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, [US/US]; 301 Binney Street, Cambridge, Massachusetts MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 02142 (US). OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (72) Inventors: XUE, Song; 18 Turner Terrace, Newton, Mass- TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. - achusetts 02460 (US). KARNATI, Vishnu Vardhan Red- = = (54) Title: NOVEL PROCESSES FOR PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS = F =R 1 /—R2 HH2N,...„0 = N N ---- CF3 = N _ N N OH = , = ../ Ra 1 10 1 = F = Formula I Compound I = F H 2 N 0 F H2N,-,0 = H -- H N CF F C 3 N \-----\ = „ N 'OH N (S) OH = (R) = — N___ -- 0' _ = .-- 0 0 M Compound IA Compound IB ei © cf•• (57) : The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble C guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyrazoles of --.... Formula (I), including Compound ( I), Compound (IA) and Compound (IB), in high purity and yields. The present invention has the 0 1-1 0 additional advantage of facile reaction conditions, amenable to scale up for large scale manufacturing. The disclosure also provides C novel intermediates useful in the preparation of said compounds. ei O [Continued on next page] WO 2018/009602 A3 MIDEDIMOMOIDEIRDERIO 011111111011101 11111 11111011111Efin (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, F1, FR, GB, GR, HR, HU, 1E, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 15 March 2018 (15.03.2018)
SG11201900125PA 2016-07-07 2017-07-06 Novel processes for preparation of soluble guanylate cyclase stimulators SG11201900125PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359430P 2016-07-07 2016-07-07
PCT/US2017/040817 WO2018009602A2 (en) 2016-07-07 2017-07-06 Novel processes for preparation of soluble guanylate cyclase stimulators

Publications (1)

Publication Number Publication Date
SG11201900125PA true SG11201900125PA (en) 2019-02-27

Family

ID=59351140

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201900125PA SG11201900125PA (en) 2016-07-07 2017-07-06 Novel processes for preparation of soluble guanylate cyclase stimulators
SG10202100168XA SG10202100168XA (en) 2016-07-07 2017-07-06 Novel processes for preparation of soluble guanylate cyclase stimulators

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202100168XA SG10202100168XA (en) 2016-07-07 2017-07-06 Novel processes for preparation of soluble guanylate cyclase stimulators

Country Status (17)

Country Link
US (2) US11834444B2 (en)
EP (1) EP3481821B1 (en)
JP (1) JP7054395B2 (en)
KR (1) KR102513357B1 (en)
CN (1) CN109563086B (en)
AU (1) AU2017292811B2 (en)
BR (1) BR112019000292A2 (en)
CA (1) CA3029376A1 (en)
CL (1) CL2019000017A1 (en)
EA (1) EA201990236A1 (en)
ES (1) ES2962829T3 (en)
IL (1) IL263994B (en)
JO (1) JOP20180126A1 (en)
MA (1) MA45593A (en)
MX (1) MX2019000138A (en)
SG (2) SG11201900125PA (en)
WO (1) WO2018009602A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017291827B2 (en) * 2016-07-07 2021-10-21 Cyclerion Therapeutics, Inc. Novel processes for preparation of soluble guanylate cyclase stimulators
WO2019161534A1 (en) * 2018-02-22 2019-08-29 Ironwood Pharmaceuticals, Inc. Novel processes and intermediates for preparation of soluble guanylate cyclase stimulators
JP7357621B2 (en) 2018-01-10 2023-10-06 サイクレリオン・セラピューティクス，インコーポレーテッド Novel processes and intermediates for preparing soluble guanylyl cyclase stimulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101955439A (en) * 2009-07-14 2011-01-26 华东理工大学 Method for resolving alpha-substituted-2-amino acetamide
JP5860459B2 (en) 2010-06-30 2016-02-16 アイアンウッド ファーマシューティカルズ インコーポレイテッド sGC stimulant
DK2663561T3 (en) 2011-01-13 2016-06-06 Novartis Ag New heterocyclic derivatives and their use in treating neurological disorders
WO2013101830A1 (en) * 2011-12-27 2013-07-04 Ironwood Pharmaceuticals, Inc. 2 - benzyl, 3 - (pyrimidin- 2 -yl) substituted pyrazoles useful as sgc stimulators
RS59981B1 (en) * 2013-03-15 2020-03-31 Cyclerion Therapeutics Inc Sgc stimulators
AU2015317824A1 (en) * 2014-09-17 2017-03-23 Cyclerion Therapeutics, Inc. Pyrazole derivatives as sGC stimulators
BR112018011154B1 (en) * 2015-11-30 2023-09-26 Cyclerion Therapeutics, Inc SOLID DISPERSIONS COMPRISING AN SGC STIMULATOR
AU2017291827B2 (en) 2016-07-07 2021-10-21 Cyclerion Therapeutics, Inc. Novel processes for preparation of soluble guanylate cyclase stimulators
KR20230074840A (en) 2016-07-07 2023-05-31 사이클리온 테라퓨틱스, 인크. Solid forms of an sgc stimulator

Also Published As

Publication number Publication date
KR20190025987A (en) 2019-03-12
EP3481821C0 (en) 2023-09-06
AU2017292811A1 (en) 2019-02-07
KR102513357B1 (en) 2023-03-24
CL2019000017A1 (en) 2019-05-03
SG10202100168XA (en) 2021-02-25
JOP20180126A1 (en) 2019-01-30
EA201990236A1 (en) 2019-08-30
EP3481821B1 (en) 2023-09-06
AU2017292811B2 (en) 2021-10-21
MA45593A (en) 2019-05-15
CA3029376A1 (en) 2018-01-11
US11834444B2 (en) 2023-12-05
MX2019000138A (en) 2019-06-10
BR112019000292A2 (en) 2019-04-16
ES2962829T3 (en) 2024-03-21
WO2018009602A3 (en) 2018-03-15
JP7054395B2 (en) 2022-04-13
CN109563086B (en) 2023-05-23
CN109563086A (en) 2019-04-02
IL263994B (en) 2021-10-31
US20210284632A1 (en) 2021-09-16
WO2018009602A2 (en) 2018-01-11
US20240199595A1 (en) 2024-06-20
IL263994A (en) 2019-01-31
JP2019524712A (en) 2019-09-05
EP3481821A2 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
SG11201908670SA (en) Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
SG11201809559UA (en) Substituted pyridines as inhibitors of dnmt1
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201810485SA (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201908604YA (en) Fused imidazo-piperidine jak inhibitor compound
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201408094YA (en) Neprilysin inhibitors
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201805595TA (en) Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201804885TA (en) Monomaleimide-functionalized platinum compounds for cancer therapy
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201806267QA (en) Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers